ArticleBMJ open2023

Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.

Sharana Mahomed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.